 |
|
|
| |
Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via
toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study
|
| |
| |
EASL 2022 June 22-26 London
You S1, Delahaye J1, Ermler M1, Singh J1, Jordan W1, Ray A1, Galwey N2, Austin D3, Theodore D4, Paff M1
1GlaxoSmithKline, Collegeville, PA, USA; 2GlaxoSmithKline, Stevenage, Hertfordshire, UK; 3GlaxoSmithKline, Brentford, Middlesex, UK; 4GlaxoSmithKline, Research Triangle Park, NC, USA
EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)
|
| |
|
|
|
|
|
